Monte Rosa Therapeutics News

UBS Adjusts Monte Rosa Therapeutics Price Target to $20 From $22, Maintains Buy Rating

MT NewswiresApr 29 22:36

Monte Rosa Therapeutics (GLUE) Gets a Buy From Piper Sandler

TipRanksApr 9 19:06

Analysts Offer Insights on Healthcare Companies: Allogene Therapeutics (ALLO), Moderna (MRNA) and Monte Rosa Therapeutics (GLUE)

TipRanksMar 19 20:11

Wells Fargo Gives a Buy Rating to Monte Rosa Therapeutics (GLUE)

TipRanksMar 15 17:17

Promising Clinical Progress and Strategic Milestones Bolster Buy Rating for Monte Rosa Therapeutics

TipRanksMar 15 04:45

Monte Rosa Therapeutics (GLUE) Receives a Buy From Piper Sandler

TipRanksMar 12 18:36

Monte Rosa Therapeutics Analyst Ratings

BenzingaFeb 15 21:32

Wedbush Starts Monte Rosa Therapeutics With Outperform Rating, $11 Price Target

MT NewswiresFeb 15 19:23

Analysts' Opinions Are Mixed on These Healthcare Stocks: Celldex (CLDX), Monte Rosa Therapeutics (GLUE) and Solid Biosciences (SLDB)

TipRanksNov 14, 2023 16:40

Analysts Offer Insights on Healthcare Companies: Vertex (VERX) and Monte Rosa Therapeutics (GLUE)

TipRanksNov 10, 2023 04:21

JP Morgan Maintains Overweight on Monte Rosa Therapeutics, Lowers Price Target to $11

BenzingaOct 20, 2023 03:08

Monte Rosa Therapeutics Analyst Ratings

BenzingaOct 20, 2023 03:07

Hold Rating on Monte Rosa Therapeutics Due to Clinical Uncertainties and Delayed Launch of MRT-2359: An Analysis

TipRanksOct 19, 2023 20:17

Credit Suisse Reiterates Neutral on Monte Rosa Therapeutics, Maintains $11 Price Target

BenzingaAug 11, 2023 21:11

Monte Rosa Therapeutics Analyst Ratings

BenzingaAug 11, 2023 21:11

Berenberg Bank Reaffirms Their Buy Rating on Monte Rosa Therapeutics (GLUE)

TipRanksMay 15, 2023 22:35

Monte Rosa Therapeutics (GLUE) Gets a Hold From SVB Securities

TipRanksMay 15, 2023 18:06

Piper Sandler Remains a Buy on Monte Rosa Therapeutics (GLUE)

TipRanksMay 12, 2023 20:15

SVB Securities Sticks to Their Hold Rating for Monte Rosa Therapeutics (GLUE)

TipRanksMar 20, 2023 22:07

Credit Suisse Maintains Neutral on Monte Rosa Therapeutics, Lowers Price Target to $11

BenzingaMar 17, 2023 22:43